Joffrey Feriel
Research Subjects
Joffrey Feriel has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
François Depasse
Medical Affairs Department, Diagnostica Stago , Asnieres sur Seine
3 shared publicationsAurélien Lebreton
CHU Clermont Ferrand, Service d’Hématologie Biologique, Unité d’hémostase Clermont Ferrand, France
2 shared publicationsBas De Laat
Synapse Research Institute, Kon. Emmaplein, Maastricht, The Netherlands
1 shared publicationClaire Hemar
Centre Hospitalier de Valenciennes, Laboratoire d'Hématologie-Hémostase, Valenciennes, France
1 shared publicationD. Loze-Warot
1 shared publicationDraga Tchipeva
Diagnostica Stago Asnieres Sur Seine France
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 37 (4) , 151-160
Performance evaluation of Stago sthemO 301 hemostasis analyzer for routine testing, coagulation factors, and inhibitors
The sthemO 301 is a new hemostasis analyzer developed by Diagnostica Stago, combining simultaneously three different methodologies (i.e. clotting, chromogenic and immunological assays) on a single platform. The objective of this evaluation was to assess the analytical performances of the sthemO 301 and to compare it with the STA R Max on a selection of 20 hemostasis parameters (PT, aPTT with two reagents, Clauss fibrinogen, thrombin time, D-dimer, anti-Xa, factors II, V, VII, X, VIII, IX and XI, antithrombin, protein C and protein S). Within-run and inter-laboratory precisions have been evaluated using quality controls. Method comparisons were performed using a minimum of 100 plasma samples, collected across multiple sites, and compared to the STA R Max analyzer. Reference intervals were determined or verified based on published data. Within-run and inter-laboratory precisions were respectively below 5.2 and 7.6% whatever the parameter and the sample used. Pearson correlation coefficient was above 0.976 for all assays and slopes ranged from 0.94 to 1.07 for all but thrombin time, which was at 0.86. Bias at levels of interest were less than 6% for most routine coagulation parameters, coagulation factors and inhibitors. We reported the precision, accuracy and reference intervals of 20 parameters on the sthemO 301, half of these being reported for the first time, which include anti-Xa, factors II, V, VII, X, VIII, IX, XI, protein S free antigen and activity. The sthemO 301 analyzer offers satisfactory analytical performance and a good comparability with the STA R Max for all parameters.
- 10 March 2026
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 37 (4) , 151-160
Open AccessPerformance evaluation of Stago sthemO 301 hemostasis analyzer for routine testing, coagulation factors, and inhibitors
The sthemO 301 is a new hemostasis analyzer developed by Diagnostica Stago, combining simultaneously three different methodologies (i.e. clotting, chromogenic and immunological assays) on a single platform. The objective of this evaluation was to assess the analytical performances of the sthemO 301 and to compare it with the STA R Max on a selection of 20 hemostasis parameters (PT, aPTT with two reagents, Clauss fibrinogen, thrombin time, D-dimer, anti-Xa, factors II, V, VII, X, VIII, IX and XI, antithrombin, protein C and protein S). Within-run and inter-laboratory precisions have been evaluated using quality controls. Method comparisons were performed using a minimum of 100 plasma samples, collected across multiple sites, and compared to the STA R Max analyzer. Reference intervals were determined or verified based on published data. Within-run and inter-laboratory precisions were respectively below 5.2 and 7.6% whatever the parameter and the sample used. Pearson correlation coefficient was above 0.976 for all assays and slopes ranged from 0.94 to 1.07 for all but thrombin time, which was at 0.86. Bias at levels of interest were less than 6% for most routine coagulation parameters, coagulation factors and inhibitors. We reported the precision, accuracy and reference intervals of 20 parameters on the sthemO 301, half of these being reported for the first time, which include anti-Xa, factors II, V, VII, X, VIII, IX, XI, protein S free antigen and activity. The sthemO 301 analyzer offers satisfactory analytical performance and a good comparability with the STA R Max for all parameters.
- Open Access
- 26 August 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (4) , 524-529
Technical features and analytical performances of the Stago Expert Preanalytical Check module for hemolysis, icterus, and lipemia measurement
Objective: Interference caused by hemolysis, icterus, and lipemia (HIL) are a common source of preanalytical errors during coagulation testing. Stago has developed a specific module on its coagulation analyzers to standardize the detection of HIL. Methods: The aims of this study were to evaluate the accuracy, carryover, and cross-interference of HIL measurement and compare results with those obtained on cobas 8000 modular analyzer series devices (Roche Diagnostics). These evaluations were carried out using Clinical and Laboratory Standards Institute guidance and regulatory study requirements. Results: We demonstrated the absence of sample carryover through the HIL measurement chamber and excellent accuracy between HIL theoretical and measured concentrations, with an R2 above 0.99 in all cases. We did not detect any cross-interference of bilirubin and lipids to hemoglobin, of hemoglobin and lipids to bilirubin, or for hemoglobin and bilirubin to lipids. We found excellent agreement between HIL on the Stago STA R Max3 and cobas 8000 platforms, with κ coefficients ranging from 0.928 to 0.963. Conclusions: These results support the implementation of the Stago Expert Preanalytical Check module for HIL interference measurement in routine coagulation laboratory testing.
- 26 August 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (4) , 524-529
Open AccessTechnical features and analytical performances of the Stago Expert Preanalytical Check module for hemolysis, icterus, and lipemia measurement
Objective: Interference caused by hemolysis, icterus, and lipemia (HIL) are a common source of preanalytical errors during coagulation testing. Stago has developed a specific module on its coagulation analyzers to standardize the detection of HIL. Methods: The aims of this study were to evaluate the accuracy, carryover, and cross-interference of HIL measurement and compare results with those obtained on cobas 8000 modular analyzer series devices (Roche Diagnostics). These evaluations were carried out using Clinical and Laboratory Standards Institute guidance and regulatory study requirements. Results: We demonstrated the absence of sample carryover through the HIL measurement chamber and excellent accuracy between HIL theoretical and measured concentrations, with an R2 above 0.99 in all cases. We did not detect any cross-interference of bilirubin and lipids to hemoglobin, of hemoglobin and lipids to bilirubin, or for hemoglobin and bilirubin to lipids. We found excellent agreement between HIL on the Stago STA R Max3 and cobas 8000 platforms, with κ coefficients ranging from 0.928 to 0.963. Conclusions: These results support the implementation of the Stago Expert Preanalytical Check module for HIL interference measurement in routine coagulation laboratory testing.
- Open Access
- 7 April 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (7) , 941
Impact of Drugs Used in Intensive Care on Routine Coagulation Testing
Coagulation testing is commonly used in the intensive care unit (ICU) to monitor and manage the hemostatic balance, assess bleeding risk, and guide anticoagulant therapy. Routine tests used for this purpose include prothrombin time, activated partial thromboplastin time, fibrinogen, and anti-Xa assays. Some of the drugs commonly used in critically ill patients may influence coagulation assays by interacting in vitro with reagents or in vivo with coagulation pathways, thus altering the coagulation cascade and the fibrinolytic pathway. While the pharmacological effects of drugs on coagulation are usually documented, to our knowledge, no comprehensive review article has been published to date. In this review, we have conducted a critical analysis of the literature to define: (1) the impact of hydroxocobalamin, intravenous lipid emulsion, and propofol on chromogenic assays; (2) the impact of PEGylated compounds, emicizumab, recombinant activated factor VII, antibiotics, and sugammadex on chronometric assays; (3) the challenges associated with bridging anticoagulation in the ICU as well as the effect of N-acetylcystein, serotonin reuptake inhibitors, and tramadol on the hemostasis system. For each drug, we specify the routine coagulation assay that is impacted, whether this is linked to an in vitro interference or an in vivo effect, and the potential consequences on patient management.
- 7 April 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (7) , 941
Open AccessImpact of Drugs Used in Intensive Care on Routine Coagulation Testing
Coagulation testing is commonly used in the intensive care unit (ICU) to monitor and manage the hemostatic balance, assess bleeding risk, and guide anticoagulant therapy. Routine tests used for this purpose include prothrombin time, activated partial thromboplastin time, fibrinogen, and anti-Xa assays. Some of the drugs commonly used in critically ill patients may influence coagulation assays by interacting in vitro with reagents or in vivo with coagulation pathways, thus altering the coagulation cascade and the fibrinolytic pathway. While the pharmacological effects of drugs on coagulation are usually documented, to our knowledge, no comprehensive review article has been published to date. In this review, we have conducted a critical analysis of the literature to define: (1) the impact of hydroxocobalamin, intravenous lipid emulsion, and propofol on chromogenic assays; (2) the impact of PEGylated compounds, emicizumab, recombinant activated factor VII, antibiotics, and sugammadex on chronometric assays; (3) the challenges associated with bridging anticoagulation in the ICU as well as the effect of N-acetylcystein, serotonin reuptake inhibitors, and tramadol on the hemostasis system. For each drug, we specify the routine coagulation assay that is impacted, whether this is linked to an in vitro interference or an in vivo effect, and the potential consequences on patient management.
- 1 February 2025
- Published by JLE in Annales de biologie clinique
- Vol. 83 (1) , 00
Multicenter analytical performance evaluation of the ST Genesia thrombin generation system
Available data on the potential use of thrombin generation (TG) assays in clinical practice is promising but larger studies involving several centers are needed to confirm this added-value for clinical purposes. The objective of this evaluation was to assess the analytical performances of the ST Genesia using STG-ThromboScreen, STG-BleedScreen, and STG-DrugScreen reagents across three centers to support its use in multicenter studies. Repeatability and reproducibility have been evaluated using commercial plasmas and quality control (QC) samples. Accuracy was assessed by calculating QC biases from the manufacturer's assigned values. Frozen plasma samples from healthy donors and patients having thrombophilia, hemorrhagic disorders, or taking anticoagulants allowed the comparison of TG parameters between the analyzers from two French centers. Repeatability and reproducibility CVs were respectively below 5% and 10% whatever the reagent and the sample used. The later fell under 6% after normalization. Mean biases between observed and assigned QC values provided by the manufacturer were less than 5% for most TG parameters. We found a good agreement for all TG parameters between the two evaluating centers. Relative bias was below 5% for all combination of parameters and reagents except for Peak height (+14.2%), ETP (+7.3%), and ETP inhibition (-12.0%) using STG-ThromboScreen. We found satisfactory repeatability, reproducibility, accuracy, and inter-laboratory variability for TG parameters using the three available reagents across three centers, supporting the use of ST Genesia in multicenter clinical trials.
- 1 February 2025
- Published by JLE in Annales de biologie clinique
- Vol. 83 (1) , 00
Multicenter analytical performance evaluation of the ST Genesia thrombin generation system
Available data on the potential use of thrombin generation (TG) assays in clinical practice is promising but larger studies involving several centers are needed to confirm this added-value for clinical purposes. The objective of this evaluation was to assess the analytical performances of the ST Genesia using STG-ThromboScreen, STG-BleedScreen, and STG-DrugScreen reagents across three centers to support its use in multicenter studies. Repeatability and reproducibility have been evaluated using commercial plasmas and quality control (QC) samples. Accuracy was assessed by calculating QC biases from the manufacturer's assigned values. Frozen plasma samples from healthy donors and patients having thrombophilia, hemorrhagic disorders, or taking anticoagulants allowed the comparison of TG parameters between the analyzers from two French centers. Repeatability and reproducibility CVs were respectively below 5% and 10% whatever the reagent and the sample used. The later fell under 6% after normalization. Mean biases between observed and assigned QC values provided by the manufacturer were less than 5% for most TG parameters. We found a good agreement for all TG parameters between the two evaluating centers. Relative bias was below 5% for all combination of parameters and reagents except for Peak height (+14.2%), ETP (+7.3%), and ETP inhibition (-12.0%) using STG-ThromboScreen. We found satisfactory repeatability, reproducibility, accuracy, and inter-laboratory variability for TG parameters using the three available reagents across three centers, supporting the use of ST Genesia in multicenter clinical trials.
- Open Access
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100988
PB1131 Clinical Performance Evaluation of the New Stago System for Prothrombin Time Determination: sthemO PT Assay on sthemO 301 Analyzer
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100988
Open AccessPB1131 Clinical Performance Evaluation of the New Stago System for Prothrombin Time Determination: sthemO PT Assay on sthemO 301 Analyzer
- Open Access
- 21 May 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 43 (5) , 917-926
Effects of circadian variation, lifestyle and environment on hematological parameters: A narrative review
The complete blood count (CBC) is the most widely prescribed laboratory test. It plays a key role in screening, diagnosing, and monitoring a variety of medical disorders. Preanalytical and analytical variables are responsible for more than 50% of laboratory errors that may lead to spurious CBC results. The effects of blood sampling, transport, storage, and analytical errors on hematological parameters have been well described. Circadian variation and changes in lifestyle and environment can also affect blood cells. It has been extensively studied in the past, but highly variable methodology and the presence of confounding factors have provided scattered and inconsistent results. We have investigated the literature to define the impact of circadian variation, modification of the sleep‐wake cycle, acute and chronic exercise, eating habits, alcohol, tobacco, drugs of abuse, high‐altitude, heat/cold exposure, and air pollution on CBC results. The affected cell type along with the intensity and duration of changes are detailed for each condition. We aim at providing a comprehensive overview of which situations may induce clinically significant changes and have to be taken into account by healthcare professionals before considering a hematological parameter as pathological and requesting complementary tests.
- 21 May 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 43 (5) , 917-926
Open AccessEffects of circadian variation, lifestyle and environment on hematological parameters: A narrative review
The complete blood count (CBC) is the most widely prescribed laboratory test. It plays a key role in screening, diagnosing, and monitoring a variety of medical disorders. Preanalytical and analytical variables are responsible for more than 50% of laboratory errors that may lead to spurious CBC results. The effects of blood sampling, transport, storage, and analytical errors on hematological parameters have been well described. Circadian variation and changes in lifestyle and environment can also affect blood cells. It has been extensively studied in the past, but highly variable methodology and the presence of confounding factors have provided scattered and inconsistent results. We have investigated the literature to define the impact of circadian variation, modification of the sleep‐wake cycle, acute and chronic exercise, eating habits, alcohol, tobacco, drugs of abuse, high‐altitude, heat/cold exposure, and air pollution on CBC results. The affected cell type along with the intensity and duration of changes are detailed for each condition. We aim at providing a comprehensive overview of which situations may induce clinically significant changes and have to be taken into account by healthcare professionals before considering a hematological parameter as pathological and requesting complementary tests.
- Open Access
- 16 December 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (3) , 237-245
How I investigate basophilia in daily practice
Basophilia is a rare disorder of the complete blood count (CBC) and its management in daily practice remains unclear. Two main factors explain this situation. On the one hand, the reliability of the basophil count is insufficient, whether it is performed by a microscopic slide examination or by a hematology analyser. On the other hand, our knowledge of conditions associated with basophilia is largely based on few case reports and on reviews that refer to older reviews. The association between basophilia and myeloid neoplasm, especially chronic myeloid neoplasm, is well established. Conversely, there are conflicting data on some benign medical conditions and it remains unclear where basophilia may be present. In this review, we have investigated the medical literature to define which medical conditions can lead to basophilia and which cannot, and we propose a practical approach to manage basophilia divided into 3 steps. First, we have to check the real existence of the basophilia by getting rid of spurious basophilia. Then, we have to look for symptoms that suggest reactive basophilia and for clue of a neoplastic cause. Finally, in case of suspicion of a myeloid neoplasm or persistence of the basophilia in the absence of a reactive cause, we have to decide which examinations need to be prescribed to confirm a neoplastic basophilia.
- 16 December 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (3) , 237-245
Open AccessHow I investigate basophilia in daily practice
Basophilia is a rare disorder of the complete blood count (CBC) and its management in daily practice remains unclear. Two main factors explain this situation. On the one hand, the reliability of the basophil count is insufficient, whether it is performed by a microscopic slide examination or by a hematology analyser. On the other hand, our knowledge of conditions associated with basophilia is largely based on few case reports and on reviews that refer to older reviews. The association between basophilia and myeloid neoplasm, especially chronic myeloid neoplasm, is well established. Conversely, there are conflicting data on some benign medical conditions and it remains unclear where basophilia may be present. In this review, we have investigated the medical literature to define which medical conditions can lead to basophilia and which cannot, and we propose a practical approach to manage basophilia divided into 3 steps. First, we have to check the real existence of the basophilia by getting rid of spurious basophilia. Then, we have to look for symptoms that suggest reactive basophilia and for clue of a neoplastic cause. Finally, in case of suspicion of a myeloid neoplasm or persistence of the basophilia in the absence of a reactive cause, we have to decide which examinations need to be prescribed to confirm a neoplastic basophilia.